Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07413666 · ClinicalTrials.gov registry record · Phase 1
A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years
A Phase 1 study of Healthy Adult Male and Female Volunteers, sponsored by Centessa Pharmaceuticals (UK) Limited.
- Recruiting
- Registry status
- Phase 1
- Development phase
- 212
- Enrollment target
- 1
- Study location
NCT07413666 is a Phase 1 study of Healthy Adult Male and Female Volunteers that is actively recruiting participants, run by Centessa Pharmaceuticals (UK) Limited. The registered enrollment target is 212 participants. The trial reports 1 study location across 1 state.
The verdict
NCT07413666, a Phase 1 study of Healthy Adult Male and Female Volunteers, is actively recruiting participants, sponsored by Centessa Pharmaceuticals (UK) Limited.
- RECRUITING
- Registry status
- Phase 1
- Development phase
- 212 participants
- Enrollment target
- 1
- Study location
Study Summary
Characterize the safety, tolerability and pharmacokinetics of ORX489 following single and multiple doses.
Conditions Studied
Interventions
- DRUG ORX489 Tablets
- OTHER Placebo Tablets
Study Locations (1)
Nebraska
- Celerion - Lincoln
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 212 participants |
| Start Date | 2026-02-25 |
| Est. Completion | 2027-06-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07413666
The ClinicalTrials.gov registry entry for NCT07413666 describes a study currently listed as recruiting, categorized as Phase 1. The registered enrollment target is 212 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Centessa Pharmaceuticals (UK) Limited, which has 6 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Healthy Adult Male and Female Volunteers appearing as the primary indexed condition, and to 2 interventions - of which ORX489 Tablets is the first listed.
NCT07413666 reports 1 study location spanning 1 distinct geographic area - top geographies include Nebraska.
Frequently Asked Questions
What is clinical trial NCT07413666 about?
NCT07413666 is a clinical study titled "A Study of ORX489 in Healthy Adult Participants, Aged 18 to 60 Years". Characterize the safety, tolerability and pharmacokinetics of ORX489 following single and multiple doses.
What is the current status of trial NCT07413666?
This trial is currently recruiting. It is a Phase 1 study. The enrollment target is 212 participants. The study started on 2026-02-25. Estimated completion is 2027-06-30.
What conditions does trial NCT07413666 study?
This clinical trial studies the following conditions: Healthy Adult Male and Female Volunteers.
What interventions are being tested in trial NCT07413666?
The interventions under investigation include: ORX489 Tablets (DRUG), Placebo Tablets (OTHER).
Who is sponsoring clinical trial NCT07413666?
This trial is sponsored by Centessa Pharmaceuticals (UK) Limited, which has 6 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT07413666 being conducted?
This trial has 1 study location across Nebraska. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Healthy Adult Male and Female Volunteers
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.